Cargando…

Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors

To investigate associations between isoniazid for latent tuberculosis and risk of severe hepatitis, affecting patients with rheumatoid arthritis or ankylosing spondylitis whose treatment includes tumor necrosis factor inhibitors. Our self-controlled case series study analyzed Taiwan’s National Healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Edward Chia-Cheng, Liang, Hsun-Yin, Huang, Ya-Chun, Huang, Wei-I., Chao, Pi-Hui, Chen, Wen-Wen, Weng, Meng-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429453/ https://www.ncbi.nlm.nih.gov/pubmed/34504225 http://dx.doi.org/10.1038/s41598-021-97444-8

Ejemplares similares

Publisher Correction: Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia‑Cheng, et al.
Publicado: (2021)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area
por: Moon, Hyung Hwan, et al.
Publicado: (2017)

A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
por: Philipose, Jobin, et al.
Publicado: (2022)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis
por: Yu, Ya-Yen, et al.
Publicado: (2019)

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

1694 Risk factors and outcomes of isoniazid hepatotoxicity in children with latent tuberculosis
por: Devrim, Ilker, et al.
Publicado: (2014)

Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital
por: Chung, Sung Jun, et al.
Publicado: (2020)

Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2020)

Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
por: Oscanoa, Teodoro J., et al.
Publicado: (2023)

Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail
por: Juarez-Reyes, Maria, et al.
Publicado: (2016)

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study
por: Lam, Chee Kin, et al.
Publicado: (2018)

Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV
por: Vojnov, Lara, et al.
Publicado: (2022)

Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
por: Liou, Bo‐Huang, et al.
Publicado: (2021)

Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review
por: Khan, Fahmi Yousef, et al.
Publicado: (2010)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
por: Lai, Chih-Cheng, et al.
Publicado: (2011)

Does an Isoniazid Prophylaxis Register Improve Tuberculosis Contact Management in South African Children?
por: van Soelen, Nelda, et al.
Publicado: (2013)

Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia
por: Geremew, Demeke, et al.
Publicado: (2022)

Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study
por: Denholm, Justin T, et al.
Publicado: (2014)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report
por: Li, Tsung-Lun, et al.
Publicado: (2021)

Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis
por: Gerona, Roy, et al.
Publicado: (2016)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid
por: de Oyarzabal, Eleane, et al.
Publicado: (2019)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Pregnancy Outcomes in HIV-Infected Women Receiving Long-Term Isoniazid Prophylaxis for Tuberculosis and Antiretroviral Therapy
por: Taylor, Allan W., et al.
Publicado: (2013)

Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis
por: Zhang, Tingting, et al.
Publicado: (2019)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan
por: Liao, Tsai-Ling, et al.
Publicado: (2016)

Isoniazid-Induced Severe Hepatotoxicity: An Infrequent but Preventable Cause of Liver Failure in Children Treated for Latent Tuberculosis Infection
por: Desrochers, Dan, et al.
Publicado: (2011)

Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review
por: Shahid, Noor ul ain, et al.
Publicado: (2022)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness
por: Nwana, Nwabunie, et al.
Publicado: (2019)

Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis
por: Séraphin, Marie Nancy, et al.
Publicado: (2019)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_99ojdvhsjo2g3cos2lu22fvk2t